Adenocarcinoma

In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored PIK3CA mutations treated with standard of care capecitabine and lapatinib combination… (full text at CIViC)

PMID 26920887 · Baselga et al., 2016 · Open in CIViC

HER2 overexpressing breast cancer cell lines with PIK3CA mutation BT474c (K111N) and HCC-1954 (H1047R) were used to establish mouse tumor xenografts. In BT474c xenografts, three dosing schedules of AZ… (full text at CIViC)

PMID 22294718 · Davies et al., 2012 · Open in CIViC

Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger seque… (full text at CIViC)

PMID 27091708 · André et al., 2016 · Open in CIViC

Targeted NGS of 17 genes was utilized to assess alterations in pre-treatment tumour biopsy samples of HER2+ breast cancers from the prospective GeparSepto (G7) trial of anti-HER2 therapy (trastuzumab/… (full text at CIViC)

PMID 41974716 · Van Mackelenbergh et al., 2026 · Open in CIViC

Targeted NGS of 17 genes was utilized to assess alterations in pre-treatment tumour biopsy samples of HER2+ breast cancers from the prospective GeparSepto (G7) trial of combination trastuzumab plus pe… (full text at CIViC)

PMID 41974716 · Van Mackelenbergh et al., 2026 · Open in CIViC

In a retrospective study of 105 HER2-positive metastic breast cancer patients treated with trastuzumab-based therapy, the presence of a PIK3CA mutation (E542K, E545K, or H1047R) was associated with a … (full text at CIViC)

PMID 21594665 · Razis et al., 2011 · Open in CIViC

The HER2 overexpressing breast cancer cell line BT-474 transduced with mutant PIK3CA H1047R demonstrated essentially normal proliferation under trastuzumab, while control cells showed negligible proli… (full text at CIViC)

PMID 17936563 · Berns et al., 2007 · Open in CIViC

In a phase 3 clinical trial (NCT00829166), metastatic HER-2 amplified breast cancer patients whose tumors harbored PIK3CA mutations treated with ado-trastuzumab emtansine (T-DM1; n=40) were associated… (full text at CIViC)

PMID 26920887 · Baselga et al., 2016 · Open in CIViC

In a preclinical study, efficacy of NVP-BEZ235 (dactolisib) monotherapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with retrovirally induced PIK3CA amplification. Auth… (full text at CIViC)

PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC

In a preclinical study, efficacy of lapatinib monotherapy was evaluated in vitro against HER2 amplified breast cancer cell lines (BT474 and SKBR3) with retrovirally induced PIK3CA expression. Authors … (full text at CIViC)

PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious (as determined by Polyphen or SIFT) C284Y mutation and a high nonsynonymous mut… (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLD1 deleterious Y956N mutation (as determined by Polyphen or SIFT), treated with pembrolizumab … (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with POLE4 deleterious A59E mutation (as determined by Polyphen or SIFT), treated with pembrolizumab m… (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

Studies submitted to cBioPortal (including 164 TCGA studies) were evaluated for POLE variants co-occurring with features of POLE-mutated tumors and co-occurring B2M variants. A single individual with … (full text at CIViC)

PMID 29320758 · Voutsadakis, 2018 · Open in CIViC

CD133 (PROM1) expression in 39 samples of hepatocellular carcinomas was correlated with JNK activity. Both were more highly expressed in patients not responding to sorafenib. CD133+ cells (sorted) wer… (full text at CIViC)

PMID 22596232 · Hagiwara et al., 2012 · Open in CIViC

Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival. Expression of 294 and 116 genes was enriched i… (full text at CIViC)

PMID 26894977 · Kwon et al., 2016 · Open in CIViC

In a study of 107 prostate adenocarcinomas, those with either hemi- or homozygous deletions of PTEN (as determined by interphase FISH) have shorter biochemical recurence-free survival than those witho… (full text at CIViC)

PMID 17700571 · Yoshimoto et al., 2007 · Open in CIViC

Case report of a 44-year-old patient with recurrent HER2-positive breast cancer. The primary tumor was HR positive; however, the metastatic tumor was HR negative. The patient was resistant to classica… (full text at CIViC)

PMID 27445490 · Sun et al., 2016 · Open in CIViC

In a preclinical study, efficacy of NVP-BEZ235 (dactolisib), lapatinib, and trastuzumab combination therapy was evaluated in vitro against HER2 amplified breast cancer cell line BT474 with shRNA-induc… (full text at CIViC)

PMID 19010894 · Eichhorn et al., 2008 · Open in CIViC

Archival tumor samples from 549 patients from the BOLERO-1 and -3 trials were analyzed for alterations in the PI3K pathway using next-generation sequencing, immunohistochemistry (IHC) and Sanger seque… (full text at CIViC)

PMID 27091708 · André et al., 2016 · Open in CIViC

Castrated mice bearing androgen-sensitive human prostate adenocarcinomas (LNCaP tumors) were treated with PI3K inhibitors (AZD8186, BYL719) and an androgen receptor inhibitor (MDV3100). Mice treated … (full text at CIViC)

PMID 25544636 · Schwartz et al., 2015 · Open in CIViC

Cancer-associated mutation of PTPN12 or reduced PTPN12 protein leads to aberrant activity of several tyrosine kinase receptors (MET, PDGFRβ, EGFR, and others). Restoring PTPN12 protein levels restrain… (full text at CIViC)

PMID 29578538 · Nair et al., 2018 · Open in CIViC

SHP-1 has been shown to be a tumor suppressor in hematopoietic cancers. Reduced SHP-1 expression in HCC correlates to aggressive tumor behavior resulting in a poor prognosis for patients.

PMID 29776962 · Wen et al., 2018 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with PXDNL deleterious P1460T mutation, treated with pembrolizumab monotherapy, was associated with a … (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

Through the histological examination of 25 patient tumor samples with hepatocellular carcinoma, the efficacy of postoperative sorafenib treatment may be correlated with higher levels of c-Raf-1 expres… (full text at CIViC)

PMID 26981887 · Lei et al., 2016 · Open in CIViC

A drug screen of triple-negative breast cancer (TNBC) cell lines found several therapies to be synthetically lethal with RB1 loss of function. Cell lines with endogenous expression of RB1 (BT20, MB453… (full text at CIViC)

PMID 29386107 · Witkiewicz et al., 2018 · Open in CIViC

A drug screen of triple-negative breast cancer (TNBC) cell lines found several therapies to be synthetically lethal with RB1 loss of function. Cell lines with endogenous expression of RB1 (BT20, MB453… (full text at CIViC)

PMID 29386107 · Witkiewicz et al., 2018 · Open in CIViC

In Capan-1 cell lines engineered to reduce pRB expression (by transfection with p16), resensitization to chemotherapy-induced apoptosis was observed. The effect was asserted to be specific to pRB depl… (full text at CIViC)

PMID 11792751 · Plath et al., 2002 · Open in CIViC

ASCL1 and RET mRNA levels were examined by microarray analysis in lung cancer samples. High expression of RET (RET-high) correlated with shorter overall survival compared to the RET-low group in patie… (full text at CIViC)

PMID 24037524 · Kosari et al., 2014 · Open in CIViC

A 78-year-old man presented with oral papillary adenocarcinoma and lung metastases that were refractory to standard treatment. Tumor sequencing showed increased MAPK activity due to RET over-expressi… (full text at CIViC)

PMID 20696054 · Jones et al., 2010 · Open in CIViC

Study describes an 18 year old never smoker patient presenting with lung adenocarcinoma. A genomic profiling assay (FoundationOne) revealed a 7-copy amplification of RICTOR as the only somatic alterat… (full text at CIViC)

PMID 26370156 · Cheng et al., 2015 · Open in CIViC

Tumor samples from 640 patients with metastatic solid tumors were prospectively analyzed with a next-generation sequencing assay to identify molecular targets. 13 (2%) of 640 patients had a RICTOR-aam… (full text at CIViC)

PMID 28028034 · Kim et al., 2017 · Open in CIViC

RIT1 mutations were identified in lung adenocarcinoma tumors lacking typical driver gene mutations. RIT1 A77P was expressed in NIH3T3 cells and induced colony formation in soft agar. Similarly, RIT1 A… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC

RIT1 mutations were identified in lung adenocarcinoma tumors lacking typical driver gene mutations. RIT1 A77S was expressed in NIH3T3 cells and induced colony formation in soft agar. Similarly, RIT1 A… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC

RIT1 mutations were identified in lung adenocarcinoma tumors lacking typical driver gene mutations. RIT1 F82L was expressed in NIH3T3 cells and induced colony formation in soft agar. Similarly, RIT1 F… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC

RIT1 mutations were identified in lung adenocarcinoma tumors lacking typical driver gene mutations. RIT1 M90I was expressed in NIH3T3 cells and induced colony formation in soft agar. Similarly, RIT1 M… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC

RIT1 mutations were identified in approx. 2% of lung adenocarcinomas (5/87 in the "oncogene negative" samples of TCGA - no RIT1 mutations were observed in 143 samples with a known driver mutation). GD… (full text at CIViC)

PMID 24469055 · Berger et al., 2014 · Open in CIViC